Aldeyra Therapeutics, Inc.
ALDX
$2.76
$0.103.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.60% | 10.30% | -108.46% | -70.04% | 41.94% |
| Total Depreciation and Amortization | 2.22% | 2.27% | 1.65% | -8.87% | 2.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -69.44% | 90.26% | 0.89% | 296.70% | -182.42% |
| Change in Net Operating Assets | -33.67% | 104.40% | 162.42% | -157.23% | 850.63% |
| Cash from Operations | -50.93% | 39.70% | -32.61% | -2,092.95% | 106.24% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -129.72% | 128.86% | 39.96% | -- | -- |
| Cash from Investing | -129.72% | 128.86% | 39.96% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,660.30% | -- | -100.00% | -39.74% | -86.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 76.99% | -- | -- | -- | -- |
| Cash from Financing | 103.95% | -- | -100.00% | 101.80% | -220.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -367.16% | 90.75% | 21.99% | -7,778.71% | 93.86% |